The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Positron Emission Tomography As an Imaging Biomarker
Abstract
Positron emission tomography (PET) allows noninvasive, quantitative studies of various biologic processes in the tumor tissue. By using PET, investigators can study the pharmacokinetics of anticancer drugs, identify various therapeutic targets and monitor the inhibition of these targets during therapy. Furthermore, PET provides various markers to assess tumor response early in the course of therapy. A significant number of studies have now shown that changes in tumor glucose utilization during the first weeks of chemotherapy are significantly correlated with patient outcome. These data suggest that PET may be used as a sensitive test to assess the activity of new cytotoxic agents in phase II studies. Furthermore, early identification of nonresponding tumors provides the opportunity to adjust treatment regimens according to the individual chemosensitivity of the tumor tissue. However, further prospective and randomized validation of PET is still required before PET controlled chemotherapy can be used in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Molecular imaging in living subjects: seeing fundamental biological processes in a new light
Massoud, T. F., & Gambhir, S. S. (2003) · Genes & Development · doi:10.1101/gad.1047403 · Cited by 2,216
Young, H., Baum, R., Cremerius, U., Herholz, K., Hoekstra, O., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,720
A combined PET/CT scanner for clinical oncology.
Beyer, T., Townsend, D. W., Brun, T., Kinahan, P. E., Charron, M., Roddy, R., Jerin, J., Young, J., Byars, L. G., & Nutt, R. (2000) · PubMed · Cited by 1,659
Akt Stimulates Aerobic Glycolysis in Cancer Cells
Elstrom, R. L., Bauer, D. E., Buzzai, M., Karnauskas, R., Harris, M. H., Plas, D. R., Zhuang, H., Cinalli, R. M., Alavi, A., Rudin, C. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2904 · Cited by 1,454
Plow, E. F., Haas, T. A., Zhang, L., Loftus, J., & Smith, J. W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.r000003200 · Cited by 1,356
Positron emission tomography provides molecular imaging of biological processes
Phelps, M. E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.16.9226 · Cited by 1,229
Imaging proliferation in vivo with [F-18]FLT and positron emission tomography
Shields, A. F., Grierson, J. R., Dohmen, B. M., Machulla, H.-J., Stayanoff, J. C., Lawhorn-Crews, J. M., Obradovich, J. E., Muzik, O., & Mangner, T. J. (1998) · Nature Medicine · doi:10.1038/3337 · Cited by 1,204
Cited by
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
New approaches and procedures for cancer treatment: Current perspectives
Debela, D. T., Muzazu, S. G., Heraro, K. D., Ndalama, M. T., Mesele, B. W., Haile, D. C., Kitui, S. K., & Manyazewal, T. (2021) · SAGE Open Medicine · doi:10.1177/20503121211034366 · Cited by 1,597
Molecular imaging in drug development
Willmann, J. K., van Bruggen, N., Dinkelborg, L. M., & Gambhir, S. S. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2290 · Cited by 1,171
Synthesis of 11C, 18F, 15O, and 13N Radiolabels for Positron Emission Tomography
Miller, P. W., Long, N. J., Vilar, R., & Gee, A. D. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200800222 · Cited by 894
Day, S. E., Kettunen, M. I., Gallagher, F. A., Hu, D.-E., Lerche, M., Wolber, J., Golman, K., Ardenkjaer-Larsen, J. H., & Brindle, K. M. (2007) · Nature Medicine · doi:10.1038/nm1650 · Cited by 883
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Palumbo, A., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G., San Miguel, J., Barlogie, B., Harousseau, J., Zonder, J. A., Cavo, M., Zangari, M., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2405062 · Cited by 840
Targeting copper in cancer therapy: ‘Copper That Cancer’
Denoyer, D., Masaldan, S., La Fontaine, S., & Cater, M. A. (2015) · Metallomics · doi:10.1039/c5mt00149h · Cited by 806
Lordick, F., Ott, K., Krause, B.-J., Weber, W. A., Becker, K., Stein, H. J., Lorenzen, S., Schuster, T., Wieder, H., Herrmann, K., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70244-9 · Cited by 804
Self-citation18F-Labeling of Arenes and Heteroarenes for Applications in Positron Emission Tomography
Preshlock, S., Tredwell, M., & Gouverneur, V. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00493 · Cited by 679
Regulation of tumor pH and the role of carbonic anhydrase 9
Swietach, P., Vaughan-Jones, R. D., & Harris, A. L. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9064-0 · Cited by 539
“[30, 31] has confirmed that elevated lactic acid production”
BackgroundSkeletal PET with18F-Fluoride: Applying New Technology to an Old Tracer
Grant, F. D., Fahey, F. H., Packard, A. B., Davis, R. T., Alavi, A., & Treves, S. T. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.037200 · Cited by 520
New approaches for imaging tumour responses to treatment
Brindle, K. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2289 · Cited by 460
Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology
Kurhanewicz, J., Vigneron, D. B., Ardenkjaer-Larsen, J. H., Bankson, J. A., Brindle, K., Cunningham, C. H., Gallagher, F. A., Keshari, K. R., Kjaer, A., Laustsen, C., et al. (2019) · Neoplasia · doi:10.1016/j.neo.2018.09.006 · Cited by 440
Kwee, T. C., Takahara, T., Ochiai, R., Nievelstein, R. A. J., & Luijten, P. R. (2008) · European Radiology · doi:10.1007/s00330-008-0968-z · Cited by 410
Boellaard, R., Oyen, W. J. G., Hoekstra, C. J., Hoekstra, O. S., Visser, E. P., Willemsen, A. T., Arends, B., Verzijlbergen, F. J., Zijlstra, J., Paans, A. M., et al. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0874-2 · Cited by 396
Kim, S., Loevner, L., Quon, H., Sherman, E., Weinstein, G., Kilger, A., & Poptani, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1287 · Cited by 392
Immunodeficiency and immunotherapy in multiple myeloma
Pratt, G., Goodyear, O., & Moss, P. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06705.x · Cited by 341
O'Day, S. J., Hamid, O., & Urba, W. J. (2007) · Cancer · doi:10.1002/cncr.23086 · Cited by 309
Tumor detection using folate receptor-targeted imaging agents
Sega, E. I., & Low, P. S. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9155-6 · Cited by 291
PET/CT imaging in cancer: current applications and future directions
Farwell, M. D., Pryma, D. A., & Mankoff, D. A. (2014) · Cancer · doi:10.1002/cncr.28860 · Cited by 230
Molecular Theranostics: A Primer for the Imaging Professional
Lee, D. Y., & Li, K. C. P. (2011) · American Journal of Roentgenology · doi:10.2214/ajr.11.6797 · Cited by 95
Warnier, C., Lemaire, C., Becker, G., Zaragoza, G., Giacomelli, F., Aerts, J., Otabashi, M., Bahri, M. A., Mercier, J., Plenevaux, A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00905 · Cited by 58
Metadata
- Authors
- Weber, W. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-07-10
- Volume
- 24
- Issue
- 20
- Pages
- 3282-3292
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2150818243
- Cited by
- 312
- References
- 101
- FWCI
- 24.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.